SuperworthGLAUKOS GKOS
- Market cap
- $10.6B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 17.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $612.8M
- +42% on a year ago
- Net margin
- −30.7%
- Free cash flow yield
- −0.1%
GLAUKOS trades at 17.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $612.8M over the last twelve months, up 42% on a year earlier with a −31% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $78M+10% | $82.4M+16% | $85.6M+16% | $95.7M+19% | $96.7M+24% | $105.5M+28% | $106.7M+25% | $124.1M+30% | $133.5M+38% | $143.1M+36% | $150.6M+41% | $185.6M+50% | |
| Cost of revenue | $18.5M+10% | $18.9M+10% | $20.3M+12% | $22.6M+12% | $22.6M+22% | $28.6M+52% | $24.3M+20% | $26.9M+19% | $28.8M+28% | $144.6M+405% | $33.3M+37% | $34M+27% |
| Gross profit | $59.5M+9% | $63.5M+18% | $65.4M+17% | $73.1M+21% | $74.1M+24% | $76.9M+21% | $82.3M+26% | $97.2M+33% | $104.7M+41% | −$1.5M | $117.2M+42% | $151.6M+56% |
| R&D | $33.3M+15% | $37.1M+4% | $30.7M−13% | $34.4M+4% | $34.7M+4% | $36.5M−1% | $32.4M+5% | $36.5M+6% | $38.1M+10% | $43.7M+20% | $44.1M+36% | $51.3M+40% |
| SG&A | $54.2M+15% | $63M+21% | $62M+16% | $66.2M+25% | $64M+18% | $69M+10% | $70.7M+14% | $83.4M+26% | $83M+30% | $94.7M+37% | $92.9M+32% | $116.1M+39% |
| −$28M+30% | −$38.6M+15% | −$39.1M+18% | −$30M+3% | −$24.7M−12% | −$28.7M−26% | −$20.7M−47% | −$22.7M−24% | −$16.4M−34% | −$139.9M+388% | −$19.9M−4% | −$17.3M−24% | |
| Interest expense | $3.4M−2% | $3.4M+1% | $3.5M+1% | $3.4M−1% | $1.7M−51% | $1.6M−54% | $1.2M−66% | $1.2M−66% | $1.2M−29% | $1.1M−27% | $1.1M−3% | $1.5M+27% |
| Pre-tax income | −$30.4M+11% | −$36.7M+18% | −$40.5M+18% | −$50.2M+55% | −$21.2M−30% | −$33.7M−8% | −$17.8M−56% | −$19.4M−61% | −$16M−25% | −$139.8M+315% | −$19.3M+8% | −$17.7M−9% |
| $37K−85% | $61K−80% | $377K−6% | $331K−24% | $177K+378% | −$114K | $326K−14% | $248K−25% | $234K+32% | −$6.2M+5303% | $484K+49% | $656K+165% | |
| Net income | −$30.4M+10% | −$36.8M+17% | −$40.8M+18% | −$50.5M+54% | −$21.4M−30% | −$33.6M−9% | −$18.1M−56% | −$19.7M−61% | −$16.2M−24% | −$133.7M+298% | −$19.8M+9% | −$18.4M−7% |
| −$0.63+9% | −$0.75+14% | −$0.82+14% | −$1.00+47% | −$0.39−38% | −$0.60−20% | −$0.32−61% | −$0.34−66% | −$0.28−28% | −$2.32+287% | −$0.34+6% | −$0.31−9% | |
| 48.7M+2% | 48.9M+2% | 49.6M+4% | 50.7M+5% | 55M+13% | 55.6M+14% | 56.6M+14% | 57.2M+13% | 57.4M+4% | 57.5M+4% | 58M+2% | 58.8M+3% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
R&D: Q1 FY15: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY16 to Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest GLAUKOS' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GKOSGLAUKOS | $10.6B | n/m | 368× | 17.2× | +42% | −30.7% | |
| PODDInsulet | $10.3B | 27.9× | 63.0× | 3.4× | +29% | 12.3% | |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | 3.5× | +20% | 17.0% | |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | 2.7× | +4% | 10.0% | |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | 2.7× | +5% | 13.5% | |
| PENPenumbra | $12.8B | 79.7× | 197× | 8.5× | +18% | 10.7% | |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | 1.7× | −1% | 17.3% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| Peer median | $10.6B | 24.8× | 41.8× | 3.4× | +6% | 11.8% |
Investors who own it
Investors we follow who held GLAUKOS at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolionew
More on GLAUKOS
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .